DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Humalog Mix50 / 50 (Insulin Lispro Subcutaneous) - Published Studies

 
 



Published Studies Related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)

Well-designed clinical trials related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. [2013]

Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. [2011.06]

Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. [2011.04]

Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. [2010.12]

Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. [2010.08]

Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. [2010.05]

Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. [2010.03]

Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. [2009.09]

Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. [2009.09]

Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. [2009.08]

Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. [2009.07]

Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. [2009.05]

Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. [2008.12]

AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. [2008.04]

Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR inhaled insulin pharmacokinetics and glucodynamics. [2008.04]

A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. [2008.02]

A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. [2008.02]

A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro. [2007.12]

Insulin glulisine: a faster onset of action compared with insulin lispro. [2007.09]

AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. [2007.07]

A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. [2007.07]

Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. [2007.03]

Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. [2007.02]

Efficacy of short term continuous subcutaneous insulin lispro versus continuous intravenous regular insulin in poorly controlled, hospitalized, type 2 diabetic patients. [2006.09]

Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. [2006.05]

Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. [2006.04]

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. [2005.10]

Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. [2005.09]

Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. [2005.08]

A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. [2005.07]

Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. [2005.05]

Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. [2005.05]

Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. [2005.05]

Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. [2004.09.01]

Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. [2004.09]

A randomised controlled trial of insulin lispro given before or after meals in pregnant women with type 1 diabetes--the effect on glycaemic excursion. [2004.06]

Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]

Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. [2004.04]

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. [2004.01]

Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. [2004]

Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. [2003.12]

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. [2003.11]

Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. [2003.06]

Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. [2002.11]

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. [2002.11]

Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. [2002.04]

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. [2002.03]

A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. [2001.11]

Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. [2001.10]

Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. [2001.07]

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. [2000.12]

Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. [2000.09]

Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. [2000.05]

Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. [1999.08]

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. [1999.05]

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. [1999.03]

Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. [1999.01]

The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. [1998.12]

Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes. [1998.10]

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. [1998.06]

Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. [1998.05]

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. [1998.05]

Effect of physicochemical variables of regular insulin formulations on their absorption from the subcutaneous tissue. [1998.04]

Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? [1998.03]

Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin. [1998.01]

Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. [1997.12]

Insulin lispro in CSII: results of a double-blind crossover study. [1997.03]

Well-designed clinical trials possibly related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)

Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. [2006.01]

What is the role of between meal snacks with intensive basal bolus regimens using preprandial lispro? [1999.04]

Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. [1997.02]

Other research related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)

Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. [2012]

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. [2011.10]

Managing diabetic ketoacidosis in non-intensive care unit setting: Role of insulin analogs. [2011.07]

Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. [2011.04]

Improvement in bedtime plasma glucose level serves as a predictor of long-term blood glucose control in patients with Type 2 diabetes: a study with monotherapy of 50/50 premixed insulin analogue three times daily injection. [2011.03]

Insulin during pregnancy, labour and delivery. [2011.02]

Systemic delivery of insulin via the nasal route using a new microemulsion system: In vitro and in vivo studies. [2010.12.01]

Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin. [2010.12]

Humalog((R)) KwikPen: an insulin-injecting pen designed for ease of use. [2010.11]

An advisory protocol for rapid- and slow-acting insulin therapy based on a run-to-run methodology. [2010.07]

Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. [2010.05]

Continuous subcutaneous insulin infusion versus multiple daily injections in pregnant women with type 1 diabetes. [2010.04]

Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. [2010.01]

Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. [2010]

Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. [2010]

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. [2009.11]

A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. [2009.11]

Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues. [2009.09]

Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. [2009.06]

Severe insulin allergy after percutaneous transluminal coronary angioplasty. [2009.03]

Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis? [2009.02]

Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. [2008.12]

Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. [2008.05.20]

Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. [2008.02]

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. [2008]

[Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus] [2008]

[Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus] [2008]

Lispro insulin-induced lipoatrophy: a new case. [2007.12]

Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26 687 children and adolescents with Type 1 diabetes in Germany and Austria. [2007.12]

Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. [2007.07]

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. [2007.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017